2 hours Corcept Therapeutics (NASDAQ:CORT) PT Raised to $76.00 MarketBeat
Truist Financial increased their price objective on Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research report on Monday.
Nasdaq 100 · Science · Truist Financial Corp (TFC)